Articles tagged "Hepatocellular carcinoma"

2019 American Transplant Congress
Outcomes of Liver Transplantation for Hepatocellular Carcinoma in Septuagenarians
M. Najjar¹, K. Bruestle¹, P. Jiang¹, E. Lieberman¹, R. Hwang¹, A. Mathur¹, E. C. Verna¹, A. Griesemer¹, B. Samstein², T. Kato¹, Y. M. Saenger¹, K. J. Halazun², J. C. Emond¹
¹Columbia University Medical Center, New York, NY, ²Weill Cornell Medicine, New York, NY
*Purpose: The impact of advanced age on liver transplantation (LT) for hepatocellular carcinoma (HCC) has not been well studied. We sought to compare post-OLT survival…
2019 American Transplant Congress
Policy Changes in Liver Graft Allocation for Hepatocellular Carcinoma in the USA: Improved Survival for African American Recipients
M. Molinari¹, D. Jorgensen¹, A. Tevar¹, C. Hughes¹, A. Humar¹, N. Jonassaint²
¹Surgery, University of Pittsburgh Medical Centre, Pittsburgh, PA, ²Medicine, University of Pittsburgh Medical Centre, Pittsburgh, PA
*Purpose: To evaluate the effect of policy changes in liver graft allocation for hepatocellular carcinoma (HCC) on the overall survival of patients of different ethnicities…
2019 American Transplant Congress
Development and Characterization of Human-Derived Xenograft Model for Hepatocellular Carcinoma
M. Nazzal¹, R. Steele², R. Ray³, N. Phillips², J. Long⁴, R. Ray²
¹Surgery, Saint Louis University, Saint Louis, MO, ²Pathology, Saint Louis University, Saint Louis, MO, ³Internal Medicine, Saint Louis University, Saint Louis, MO, ⁴Comparative Medicine, Saint Louis University, Saint Louis, MO
*Purpose: Hepatocellular carcinoma (HCC) is rising in the USA and treatment options are limited. There is no convenient animal model for HCC to study novel…
2019 American Transplant Congress
Long Term Impact of Intraoperative Autologous Blood Transfusion on HCC Recurrence in Liver Transplantation
G. Kelly¹, J. L. Pasko¹, E. Dewey², E. Maynard¹, S. L. Orloff¹, C. Enestvedt¹
¹Division of Abdominal Transplant, OHSU, Portland, OR, ²Department of General Surgery, OHSU, Portland, OR
*Purpose: The aim of this study was to determine whether intraoperative autologous transfusion in liver transplant patients with HCC affects the rate of recurrence.*Methods: We…
2019 American Transplant Congress
DOME: A New Strategy for Prioritizing Hepatocellular Carcinoma Patients on the Liver Transplant Waitlist
C. Rickert¹, M. Akan², Z. Leung³, J. F. Markmann¹, S. Tayur², H. Zhao³, H. Yeh¹
¹Massachusetts General Hospital, Boston, MA, ²Tepper School of Business, Carnegie Mellon University, Pittsburgh, PA, ³City University of Hong Kong, Hong Kong, China
*Purpose: Currently, adult HCC patients are prioritized for liver transplantation by receiving MELD exception points, determined primarily by time on waitlist without regard to actual…
2019 American Transplant Congress
Outcome Of Living Donor Liver Transplantation In Elderly Patients >65 Years With And Without Hepatocellular Carcinomas: A Retroepsective Analysis
A. Thorat, L. Jeng, S. Hsu, H. Yang, C. Yeh, T. Chen, K. Poon, P. Li
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan
*Purpose: The elderly patients > 65 years with end-stage liver disease that require liver transplantation has been steadily increased over last decade in Taiwan and…
2019 American Transplant Congress
Adjuvant Immunotherapeutic Approach For Liver Transplant Recipients With Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, R. Hotta¹, Y. Imaoka¹, K. Sato¹, Y. Tanaka¹, A. G. Tzakis², S. Nishida³, H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²Cleveland Clinic Florida, Weston, FL, ³New York Medical College, Valhalla, NY
*Purpose: Although liver transplantation (LT) is a preferred treatment for selected patients with Hepatocellular carcinoma (HCC), HCC-recurrence would be a still important medical problem. Most…
2019 American Transplant Congress
Favorable Outcome of Pathologic Downstaging by Locoregional Treatment for Hepatocellular Carcinoma in Liver Transplantation
D. Kim, J. Lee, S. Kim, K. In, D. Joo, S. Kim, M. Kim
Severance hospital, Seoul, Korea, Republic of
*Purpose: There was no distinct guideline how to take into account the effect of pretransplant locoregional treatment (LRT) in hepatocellular carcinoma (HCC) staging system. The…
2019 American Transplant Congress
Prospective Multi-Regional Study of Down-Staging of Hepatocellular Carcinoma to within Milan Criteria before Liver Transplantation
N. Mehta¹, J. Guy², C. Frenette³, P. Tabrizian⁴, M. Hoteit⁵, R. Dhanasekaran⁶, J. Dodge¹, M. L. Holzner⁴, L. Frankul³, S. Florman⁴, N. Parikh⁷, F. Yao¹
¹UCSF, San Francisco, CA, ²CPMC, San Francisco, CA, ³Scripps Hospital, La Jolla, CA, ⁴Mt Sinai, New York, NY, ⁵U. Pennsylvania, Philadelphia, PA, ⁶Stanford, Palo Alto, CA, ⁷U. Michigan, Ann Arbor, MI
*Purpose: Recent studies from United Network of Organ Sharing (UNOS) Region 5 reported excellent outcomes after liver transplantation (LT) after successful down-staging in HCC patients…
2019 American Transplant Congress
Tumor Necrosis as a Result to Pre-Transplant Bridging Treatment for Hepatocellular Carcinoma and Its Effect on Post-Transplant Outcome
S. Radunz¹, A. Kirschner¹, J. M. Theysohn², C. Schotten³, T. Benkö¹
¹General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germany, ²Diagnostic and Interventional Radiology and Neurradiology, University Hospital Essen, Essen, Germany, ³Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany
*Purpose: As a bridge to liver transplantation, locoregional treatments are commonly employed in hepatocellular carcinoma (HCC) patients to prevent tumor progression during waiting time. Objective…